MELKIN Pharma develops an already validated and patented concept of innovative drugs that selectively interfere with substrates of interest downstream of ERK, without global inhibition of the entire cascade. As such, these compounds are highly specific of one particular cellular response, reducing off-target toxicity and deleterious side effects of the classical ERK inhibitors. Numerous pathologies involve dysregulation of this pathway and represent as many potential targets for Pepsignal®. PepFos has been successfully tested in different tumor models (Cancer indication). PepElk exhibited interesting properties in the field of depression and drug abuse (central functions, neurology). Pepsignal® is based on the use of synthetic peptides that can be delivered by systemic administration.